China-based baby care products manufacturer Biostime International Holdings Inc. suffered a major loss in the stock markets following news the company is under investigation for possible anticompetitive conduct. According to reports, Biostime shares dropped up to 10 percent – its deepest drop in nearly two years – as the National Development and Reform Commission is looking into the firm for allegations of price-fixing. The case follows just months after Kweichow Moutai and Wuliangye Yibin were both fined by regulators for setting minimum retail prices, say reports.
Featured News
France Competition Watchdog Dismisses Qwant Complaint Against Microsoft
Dec 21, 2025 by
CPI
US Regulators Clear Nvidia–Intel Technology Tie-Up
Dec 21, 2025 by
CPI
European Union Reaches Landmark Agreement on Digital Euro Framework
Dec 21, 2025 by
CPI
Trump Announces New Drug Pricing Deals With Major Pharmaceutical Companies
Dec 21, 2025 by
CPI
Coinbase Sues Three States Over Prediction Market Regulations
Dec 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi